TARA PARTRIDGE MERSINO
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family OPELIKA, AL NPI 1124864673
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family AL Esperion Therapeutics, Inc. All categories
General Payments — all program years on this page
$154.98
- Category: General Payments
- Program years: PY2024
- Record count: 8
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $154.98 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $154.98 | 8 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Esperion Therapeutics, Inc. | $38.99 | 2 |
| Acerta Pharma LLC | $37.31 | 2 |
| Xeris Pharmaceuticals, Inc. | $23.09 | 1 |
| ABBVIE INC. | $22.75 | 1 |
| Novo Nordisk AS | $18.11 | 1 |
| Daiichi Sankyo Inc. | $14.73 | 1 |
By program year
| Program year | Amount | Records |
|---|---|---|
| 2024 | $154.98 | 8 |
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1089456642 | Daiichi Sankyo Inc. | $14.73 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1100440717 | Novo Nordisk Inc | $18.11 | 09/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1105713380 | AstraZeneca Pharmaceuticals LP | $18.66 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1105788032 | AstraZeneca Pharmaceuticals LP | $18.65 | 10/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1107653170 | ABBVIE INC. | $22.75 | 09/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1129472370 | Esperion Therapeutics, Inc. | $24.39 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1129472372 | Esperion Therapeutics, Inc. | $14.60 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1144639682 | Xeris Pharmaceuticals, Inc. | $23.09 | 10/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.